甲磺酸达拉非尼

Tier B — Position early

Dabrafenib Mesylate · all drugs expiring in 2029 →

葛兰素史克

Originator

2013

First approval

2029

Expiry (public)

$2.21B ▲

Peak sales

化学药

Type

Targets：C-Raf、B-raf

Brand：Taffiner、Tafinlar、泰菲乐、Tafinra、Tafinrar

Indications (approved)：甲状腺瘤、结直肠癌、胶质瘤、甲状腺未分化癌、实体瘤、非小细胞肺癌、黑色素瘤

Regional status

批准上市

2013-05-29

批准上市

2013-08-26

China

批准上市

2019-12-18

Japan

批准上市

2016-03-28

Synthetic routes & intermediates2 routes

Originator routes × 1Optimised (non-patent) × 1Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 2Steps 6 · Total yield 2.39 g

Code	CAS No.	Intermediate
DABF-002	60230-36-6 Available	2,6-difluorobenzene-1-sulfonyl chloride
DABF-005	630-22-8 Available	2,2-dimethylpropanethioamide
DABF-008	1195768-18-3 Available	methyl 3-amino-2-fluorobenzoate
DABF-009	1195768-19-4 Available	methyl 3-(2,6-difluorophenylsulfonamido)-2-fluorobenzoate
DABF-010	13036-57-2 Available	2-chloro-4-methylpyrimidine
DABF-011	1195768-20-7 Available	N-(3-(2-(2-chloropyrimidin-4-yl)acetyl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide
DABF-012	1622082-84-1 Available	N-(3-(2-bromo-2-(2-chloropyrimidin-4-yl)acetyl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide
DABF-013	1195768-23-0 Available	N-(3-(2-(tert-butyl)-5-(2-chloropyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide

OptimisedRoute 1Steps 5 · Total yield 3.58 g

Synthetic routes & intermediates Route 1

Code	CAS No.	Intermediate
DABF-001	1567366-22-6 Available	ethyl 3-(3-amino-2-fluorophenyl)-3-oxopropanoate
DABF-002	60230-36-6 Available	2,6-difluorobenzene-1-sulfonyl chloride
DABF-003	1567366-18-0 Available	ethyl 3-(3-(2,6-difluorophenylsulfonamido)-2-fluorophenyl)-3-oxopropanoate
DABF-005	630-22-8 Available	2,2-dimethylpropanethioamide
DABF-006	1567366-20-4 Available	ethyl 2-(tert-butyl)-4-(3-(2,6-difluorophenylsulfonamido)-2-fluorophenyl)thiazole-5-carboxylate
DABF-007	1567366-21-5 Available	N-(3-(5-acetyl-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide

Frequently asked questions

What are the approved indications of Dabrafenib Mesylate?

Approved indications include: 甲状腺瘤, 结直肠癌, 胶质瘤, 甲状腺未分化癌, 实体瘤, 非小细胞肺癌, 黑色素瘤.

When does the Dabrafenib Mesylate patent expire?

Based on public sources, the Dabrafenib Mesylate patent expires in 2029.

How many synthesis routes are recorded for Dabrafenib Mesylate?

2 synthesis routes are recorded; the shortest is 5 steps with 3.58 g total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Dabrafenib Mesylate intermediates?

12 intermediate CAS of Dabrafenib Mesylate are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Dabrafenib Mesylate intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-24